Pavion Blue Capital LLC Has $1.60 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Pavion Blue Capital LLC decreased its position in Eli Lilly and Company (NYSE:LLY) by 38.8% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,800 shares of the company’s stock after selling 1,143 shares during the period. Pavion Blue Capital LLC’s holdings in Eli Lilly and Company were worth $1,595,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. M&G Plc acquired a new stake in Eli Lilly and Company during the 1st quarter worth approximately $8,896,000. Virtu Financial LLC acquired a new stake in shares of Eli Lilly and Company during the first quarter worth $2,138,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Eli Lilly and Company by 19.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock worth $7,699,000 after acquiring an additional 1,620 shares during the period. Mutual Advisors LLC lifted its position in Eli Lilly and Company by 404.8% in the 1st quarter. Mutual Advisors LLC now owns 62,598 shares of the company’s stock valued at $48,699,000 after acquiring an additional 50,197 shares in the last quarter. Finally, Private Advisor Group LLC boosted its stake in Eli Lilly and Company by 0.6% in the 1st quarter. Private Advisor Group LLC now owns 76,282 shares of the company’s stock worth $59,345,000 after purchasing an additional 430 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $892.70 on Friday. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53. The firm has a market capitalization of $848.45 billion, a price-to-earnings ratio of 109.94, a P/E/G ratio of 3.24 and a beta of 0.42. The stock’s 50 day moving average price is $919.74 and its two-hundred day moving average price is $862.48. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. On average, analysts anticipate that Eli Lilly and Company will post 14.05 earnings per share for the current year.

Analyst Ratings Changes

LLY has been the topic of a number of research reports. Berenberg Bank boosted their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $1,025.00 target price on shares of Eli Lilly and Company in a research note on Thursday, October 3rd. Wells Fargo & Company raised their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Bank of America boosted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, JPMorgan Chase & Co. raised their target price on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,013.41.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.